Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Vor Biopharma Inc (VOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: VOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $50.33
1 Year Target Price $50.33
| 0 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.68% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 179.23M USD | Price to earnings Ratio - | 1Y Target Price 50.33 |
Price to earnings Ratio - | 1Y Target Price 50.33 | ||
Volume (30-day avg) 5 | Beta 2.08 | 52 Weeks Range 2.62 - 65.80 | Updated Date 12/6/2025 |
52 Weeks Range 2.62 - 65.80 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -386.86 |
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.104 | Actual -121.63 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -144.27% | Return on Equity (TTM) -125.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19056461 | Price to Sales(TTM) - |
Enterprise Value 19056461 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.09 | Shares Outstanding 21910630 | Shares Floating 8911499 |
Shares Outstanding 21910630 | Shares Floating 8911499 | ||
Percent Insiders 8.98 | Percent Institutions 26.84 |
Upturn AI SWOT
Vor Biopharma Inc
Company Overview
History and Background
Vor Biopharma, Inc. is a clinical-stage cell and gene therapy company founded in 2016 and based in Cambridge, Massachusetts. It focuses on developing engineered hematopoietic stem cell (eHSC) therapies to treat hematological malignancies, aiming to improve outcomes for patients undergoing hematopoietic stem cell transplantation (HSCT).
Core Business Areas
- Engineered Hematopoietic Stem Cell (eHSC) Therapies: Vor Biopharma is focused on developing eHSC therapies to protect patients undergoing HSCT from relapse. Their lead product candidate is VOR33, an eHSC product designed to eliminate target cancer cells from the patient's body.
Leadership and Structure
Robert Ang, MD, PhD is the President and CEO. The leadership team consists of various executives in research, development, and operations. The company operates with a structure common for clinical-stage biotech firms, focused on R&D and clinical trials.
Top Products and Market Share
Key Offerings
- VOR33: VOR33 is Vor Biopharma's lead product candidate, an eHSC therapy in clinical development for acute myeloid leukemia (AML). It is designed to enable targeted cancer therapies. As a pre-commercial product, there is no market share data. Competitors include companies developing other AML therapies, like Bristol Myers Squibb (Onureg) and AbbVie/Roche (Venclexta).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with a focus on developing innovative therapies for unmet medical needs. Vor Biopharma operates within the cell and gene therapy segment, specifically targeting hematological malignancies.
Positioning
Vor Biopharma is positioned as an innovator in the eHSC therapy space. Their competitive advantage lies in their unique approach to engineering hematopoietic stem cells to improve HSCT outcomes and enable targeted therapies.
Total Addressable Market (TAM)
The global market for acute myeloid leukemia (AML) treatment is significant, projected to reach billions of dollars. Vor Biopharma's positioning is focused on capturing a portion of this market by improving HSCT outcomes and enabling targeted therapies. The actual value of TAM depends on clinical success and regulatory approval of VOR33
Upturn SWOT Analysis
Strengths
- Novel eHSC technology platform
- Focus on unmet need in hematological malignancies
- Experienced leadership team
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- High cash burn rate
Opportunities
- Potential for breakthrough therapy designation
- Partnerships with larger pharmaceutical companies
- Expansion to other hematological malignancies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- BMY
- ABBV
- ARRY
Competitive Landscape
Vor Biopharma's advantage is its novel eHSC platform. Disadvantages include the risks associated with clinical-stage companies and competition from established therapies.
Growth Trajectory and Initiatives
Historical Growth: Vor Biopharma's growth is characterized by advancing its eHSC platform and progressing VOR33 through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approval of VOR33. Analyst estimates vary depending on the perceived likelihood of success. The growth trajectory depends entirely on VOR33 progressing through trials and regulatory approval.
Recent Initiatives: Recent initiatives include advancing the Phase 1/2 clinical trial of VOR33, presenting data at scientific conferences, and securing additional funding.
Summary
Vor Biopharma is a clinical-stage company pioneering eHSC therapies, with a focus on improving HSCT outcomes in hematological malignancies. The company's success hinges on the progression of VOR33 through clinical trials. They face risks common to biotech firms, including clinical trial setbacks and funding challenges. A successful clinical trial and a commercialization strategy are key. They should be aware of the competitors in the space.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vor Biopharma Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-02-05 | Chairman & CEO Dr. Jean-Paul Kress M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 154 | Website https://www.vorbio.com |
Full time employees 154 | Website https://www.vorbio.com | ||
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.